ADIAL PHARMACEUTICALS, INC. Files 8-K Report
Ticker: ADIL · Form: 8-K · Filed: Jan 8, 2025 · CIK: 1513525
| Field | Detail |
|---|---|
| Company | Adial Pharmaceuticals, Inc. (ADIL) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, financials
Related Tickers: ADIL
TL;DR
Adial Pharma filed an 8-K on Jan 8, 2025 - mostly standard disclosures.
AI Summary
On January 8, 2025, ADIAL PHARMACEUTICALS, INC. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with a Regulation FD disclosure. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Adial Pharmaceuticals has submitted required regulatory documentation, which may contain updates on financial status or other material information for investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, with no immediate indication of significant positive or negative developments.
Key Players & Entities
- ADIAL PHARMACEUTICALS, INC. (company) — Registrant
- January 8, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-38323 (identifier) — Commission File Number
- 82-3074668 (identifier) — IRS Employer Identification No.
- 4870 Sadler Road , Ste 300 Glen Allen , VA 23060 (address) — Principal Executive Offices
- ( 804 ) 487-8196 (phone_number) — Business Phone
FAQ
What is the primary purpose of this 8-K filing by ADIAL PHARMACEUTICALS, INC.?
The filing is a Current Report on Form 8-K, primarily for Regulation FD Disclosure and Financial Statements and Exhibits, filed as of January 8, 2025.
When was this 8-K report filed?
The report was filed as of January 8, 2025.
In which state is ADIAL PHARMACEUTICALS, INC. incorporated?
ADIAL PHARMACEUTICALS, INC. is incorporated in Delaware.
What is the Commission File Number for ADIAL PHARMACEUTICALS, INC.?
The Commission File Number for ADIAL PHARMACEUTICALS, INC. is 001-38323.
What is the address of ADIAL PHARMACEUTICALS, INC.'s principal executive offices?
The address of the principal executive offices is 4870 Sadler Road, Ste 300, Glen Allen, VA 23060.
Filing Stats: 645 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2025-01-08 16:38:20
Filing Documents
- ea0227224-8k_adial.htm (8-K) — 25KB
- ea022722401ex99-1_adial.htm (EX-99.1) — 35KB
- ex99-1_001.jpg (GRAPHIC) — 318KB
- ex99-1_002.jpg (GRAPHIC) — 373KB
- ex99-1_003.jpg (GRAPHIC) — 137KB
- ex99-1_004.jpg (GRAPHIC) — 324KB
- ex99-1_005.jpg (GRAPHIC) — 314KB
- ex99-1_006.jpg (GRAPHIC) — 293KB
- ex99-1_007.jpg (GRAPHIC) — 265KB
- ex99-1_008.jpg (GRAPHIC) — 330KB
- ex99-1_009.jpg (GRAPHIC) — 278KB
- ex99-1_010.jpg (GRAPHIC) — 188KB
- ex99-1_011.jpg (GRAPHIC) — 210KB
- ex99-1_012.jpg (GRAPHIC) — 247KB
- ex99-1_013.jpg (GRAPHIC) — 284KB
- ex99-1_014.jpg (GRAPHIC) — 293KB
- ex99-1_015.jpg (GRAPHIC) — 312KB
- ex99-1_016.jpg (GRAPHIC) — 273KB
- ex99-1_017.jpg (GRAPHIC) — 211KB
- ex99-1_018.jpg (GRAPHIC) — 245KB
- ex99-1_019.jpg (GRAPHIC) — 223KB
- ex99-1_020.jpg (GRAPHIC) — 160KB
- 0001213900-25-002106.txt ( ) — 7510KB
- adil-20250108.xsd (EX-101.SCH) — 3KB
- adil-20250108_lab.xml (EX-101.LAB) — 33KB
- adil-20250108_pre.xml (EX-101.PRE) — 22KB
- ea0227224-8k_adial_htm.xml (XML) — 4KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. Adial Pharmaceuticals, Inc. (the "Company") has updated its corporate presentation. A copy of the updated corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and in the corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are "forward-looking" rather than historical. The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time if its management believes it is appropriate. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases or through other public disclosures.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits . (d) Exhibits. Exhibit No. Description 99.1 Corporate Presentation of Adial Pharmaceuticals, Inc., dated January 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 8, 2025 ADIAL PHARMACEUTICALS, INC. By: /s/ Cary J. Claiborne Name: Cary J. Claiborne Title: President and Chief Executive Officer 2